- PhRMA report lists 271 vaccines in development
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Pairing influenza and pneumococcal vaccination shots for children raises risk of fever
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.
ACIP now recommends the use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13) for high-risk adults ages 19 years or older. The committee recommends that PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23), the vaccine currently recommended for these groups of adults.
Those at high risk include patients with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks or cochlear implants.
Click here to access the report, which outlines the new ACIP recommendations for PCV13 use, explains the recommendations for the use of PCV13 and PPSV23 among high-risk adults, and summarizes the evidence.